Business Wire

BALDERTON-CAPITAL

7.2.2020 13:03:07 CET | Business Wire | Press release

Share
Balderton Capital, Europe’s Most Active Series A Investor, Welcomes Two New General Partners

Balderton Capital announces today that it has hired two new General Partners. Rana Yared joins from Goldman Sachs, where she was Partner in the Principal Strategic Investments team. David Thévenon joins from SoftBank’s Vision Fund, where he was one of the initial Partners.

Bernard Liautaud, Managing Partner of Balderton Capital, said: "I am delighted to welcome Rana and David to the partnership. They both bring outstanding experience in investing globally in the technology ecosystem. With her team at Goldman Sachs, Rana has built one of the best fintech and AI portfolios across the US and Europe. And within Softbank, David has participated in the growth journeys of companies as diverse as Didi in China, Grab in Singapore, Lemonade and SoFi in the US. The opportunity in the European tech ecosystem continues to expand at a rapid pace, and Rana and David will play a key role in our investment strategy in the European venture space."

During her time at Goldman Sachs, Rana’s team invested $2bn in 80 companies, with a strong focus on fintech. As one of Goldman’s best-known tech investors, Rana led the US and European Principal Strategic Investment (PSI) teams and served on Goldman’s Growth Equity Investment committee. She spent five years on the board of the fixed income trading platform Tradeweb, until it went public in April 2019 with a market capitalisation of $6bn. Rana also brought the artificial intelligence platform Kensho to Goldman Sachs. Kensho was ultimately sold to S&P Global for $550m in March 2018.

Rana currently sits on the boards of Nutmeg, Vestwell, NAV, Pensando, Digital Reasoning, Veem, and NYSHEX. She joined Goldman Sachs as an analyst in 2006 and was named Managing Director in 2013 and Partner in 2018.

Rana Yared said: “My greatest passion is working closely with founders and their teams to build new companies, and I am delighted to be able to devote myself to this when I join Balderton. In recent years, Europe has established itself as a tech leader and is brimming with potential and opportunity. I am excited to move back to the European side of the Atlantic and to begin seeking out and working with the next generation of exciting tech companies.”

During his five-year tenure at SoftBank, David led investments in Didi Chuxing, the world's leading mobile transportation platform; Grab, Southeast Asia's leading superapp; Ola, India's leading ride-sharing platform; Lemonade, the digital insurance company powered by AI and driven by social good; SoFi, the American online personal finance platform; and Kabbage, one of the leading US SMB lending platforms. David was also involved in SoftBank's investments in 99 in Brazil (bought by Didi) and Legendary Pictures in the US (sold to Wanda Group).

Before joining SoftBank, David had a 10-year career at Google, where he worked on partnerships for products that touched billions of users, including leading global product and business partnerships for Google's Android platform.

David Thévenon said: “Five years ago I left Google to focus on venture investing at SoftBank and I felt privileged to meet, invest and work with some of the most innovative and visionary founders, supporting them as they grew into market-leading companies. Joining Balderton will allow me to continue this for European-founded companies, and I am truly excited about the opportunity ahead.”

[ENDS]

About Balderton:
Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. Balderton’s most recent funds were the early-stage Balderton VII, raised in November 2019, and Liquidity I, Europe’s first venture fund dedicated to secondary investments in European-founded, growth-stage technology startups, raised in October 2018. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Darktrace, Depop, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Peakon, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, Vestiaire Collective, Vivino, Voi Technology, and Zego.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye